Table 1. Percentage Annexin V-positive (early apoptotic) ECV304 and H292 cells 72 h after treatment with gemcitabine for 24 h and/or radiotherapy.
dFdC immediately before RT | 0 Gy | 2 Gy | 6 Gy |
---|---|---|---|
ECV304 | |||
0 nM | 9.17±2.38 | 10.86±1.74 | 18.76±5.87* |
2 nM | 10.20±1.36 | 11.18±2.33 | 17.19±2.30† |
8 nM | 14.28±1.68* | 18.34±8.41§ | 31.83±7.31§,∣∣ |
H292 | |||
0 nM | 4.00±1.55 | 6.52±2.39 | 13.53±4.04* |
4 nM | 4.77±0.72 | 5.55±1.51 | 15.61±1.20†† |
18 nM | 20.06±5.09* | 26.94±5.34** | 38.26±7.82∣∣,§§ |
dFdC immediately after RT | |||
ECV304 | |||
0 nM | 12.67±2.93 | 12.56±4.50 | 23.16±2.70 |
2 nM | 5.73±3.40 | 13.06±4.57 | 19.18±7.33 |
8 nM | 7.35±5.35 | 7.30±4.13 | 17.18±7.07 |
H292 | |||
0 nM | 4.02±1.94 | 5.68±4.37 | 9.49±4.66 |
4 nM | 3.42±1.91 | 2.20±0.75 | 5.60±3.12 |
18 nM | 5.26±1.24 | 7.24±5.55 | 11.42±1.33§§ |
*P<0.05 vs 0 nM+0 Gy, †P<0.05 vs 2 nM+0 Gy, §P<0.05 vs 8 nM+0 Gy, ∣∣P<0.05 vs 0 nM+6 Gy, **P<0.05 vs 0 nM+2 Gy, ††P<0.05 vs 4 nM+0 Gy, §§P<0.05 vs 18 nM+0 Gy.